We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
976
Owens Corning
OC
$11B
| – | – |
-32,639
| Closed | -$4.6M |
|
977
On Holding
ONON
$12.6B
| – | – |
-768,053
| Closed | -$33.5M |
|
978
Paylocity
PCTY
$7.75B
| – | – |
-4,424
| Closed | -$705K |
|
|
PGRE
979
DELISTED
Paramount Group
PGRE
| – | – |
-59,889
| Closed | -$390K |
|
980
Prenetics Global
PRE
$306M
| – | – |
-73,621
| Closed | -$979K |
|
981
Perrigo
PRGO
$1.44B
| – | – |
-28,292
| Closed | -$615K |
|
|
REVG
982
DELISTED
REV Group
REVG
| – | – |
-552,010
| Closed | -$31.1M |
|
|
RNAM
983
DELISTED
Avidity Biosciences
RNAM
| – | – |
-304,828
| Closed | -$13.3M |
|
984
Rhythm Pharmaceuticals
RYTM
$7.31B
| – | – |
-26,740
| Closed | -$2.7M |
|
985
Sutro Biopharma
STRO
$386M
| – | – |
-6,939
| Closed | -$60.3K |
|
986
Tarsus Pharmaceuticals
TARS
$2.55B
| – | – |
-51,678
| Closed | -$3.07M |
|
987
Tenaya Therapeutics
TNYA
$160M
| – | – |
-600,700
| Closed | -$973K |
|
988
Tradeweb Markets
TW
$23B
| – | – |
-9,213
| Closed | -$1.02M |
|
989
Ternium
TX
$9.43B
| – | – |
-8,135
| Closed | -$281K |
|
990
Veracyte
VCYT
$4.45B
| – | – |
-162,102
| Closed | -$5.56M |
|
|
WNS
991
DELISTED
WNS Holdings
WNS
| – | – |
-5,884
| Closed | -$448K |
|
992
Xencor
XNCR
$1.45B
| – | – |
-558,810
| Closed | -$6.55M |
|
|
ZK
993
DELISTED
Zeekr
ZK
| – | – |
-8,863
| Closed | -$260K |
|
|
PVLA
994
Palvella Therapeutics
PVLA
$2.05B
| – | – |
-51,243
| Closed | -$3.21M |
|
|
RAL
995
Ralliant Corp
RAL
$7.5B
| – | – |
-38,792
| Closed | -$1.66M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.